More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurrence should, therefore, include novel techniques such as PET imaging and genomic analysis of radical prostatectomy specimen tissue, as well as consideration of more traditional clinical variables such as PSA value, PSA kinetics, Gleason score and pathological stage of disease. In patients without metastatic disease, the only known curative intervention is salvage radiotherapy but, given the therapeutic burden of this treatment, importance must be placed on accurate timing of treatment, radiation dose, fractionation and field size. Systemic therapy also has a role in the salvage setting, both concurrently with radiotherapy and as salvage monotherapy.

超过 40% 的中危或高危前列腺癌男性在根治性前列腺切除术后会出现生化复发。管理这些患者的临床指南主要集中在使用或不使用全身治疗的挽救性放射治疗上。然而，并非所有生化复发的患者都会继续发生转移或死于疾病。因此，对于经历生化复发的患者，最佳的抢救前治疗研究检查应包括新技术，如 PET 成像和根治性前列腺切除术标本组织的基因组分析，以及考虑更传统的临床变量，如 PSA 值、PSA 动力学, Gleason 评分和疾病的病理分期。在没有转移性疾病的患者中，唯一已知的治疗性干预是抢救性放射治疗，但鉴于这种治疗的治疗负担，必须重视治疗的准确时间、放射剂量、分割和射野大小。全身治疗在挽救环境中也有作用，既可以与放疗同时进行，也可以作为挽救性单一疗法。